Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
In: BMC Cancer, Jg. 14 (2014-10-02), S. 1-8
Online
academicJournal
Zugriff:
Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC). Methods: 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750 mg/m² oral BD days 1-7)oxaliplatin (85 mg/m²i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle (C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m²oral BD (C1500) and 30 further patients recruited. Methods: 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750 mg/m² oral BD days 1-7)oxaliplatin (85 mg/m²i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle (C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m²oral BD (C1500) and 30 further patients recruited. Conclusions: Dose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and has potentially significant toxicity. Its use outside of clinical trials is not recommended. [ABSTRACT FROM AUTHOR]
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
|
---|---|
Autor/in / Beteiligte Person: | Jackson, Christopher G. C. A. ; Sharples, Katrina ; Thompson, Paul I. ; O'Donnell, Anne ; Robinson, Bridget Anne ; Perez, David J. ; Adams, Jacqui ; Isaacs, Richard ; Deva, Sanjeev ; Hinder, Victoria A. ; Findlay, Michael P. |
Link: | |
Zeitschrift: | BMC Cancer, Jg. 14 (2014-10-02), S. 1-8 |
Veröffentlichung: | 2014 |
Medientyp: | academicJournal |
ISSN: | 1471-2407 (print) |
DOI: | 10.1186/1471-2407-14-737 |
Schlagwort: |
|
Sonstiges: |
|